Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BioRestorative Therapies, Inc.
Report date October 06, 2025 · Filed October 20, 2025
Section 16 reporting ended · disclosed 2025-10-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Comon StockSEC Table I · non-derivative | Direct | 171,384 |
Reported balance
After 2025-10-06 transaction · row 1
1 source rowRow 1 · 2025-10-06 · Grant · Acquired 11,719 · Balance 171,384 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $2.75 · Expires 2030-10-08 | Direct | 11,719 |
Reported balance
After 2025-10-06 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-10-06 · Grant · Acquired 11,719 · Balance 11,719 |
| Common StockSEC Table I · non-derivative | IndirectIRA | 12,136 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 12,136 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3,000.00 · Expires 2026-06-10 | Direct | 15 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 15 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3,000.00 · Expires 2027-07-12 | Direct | 20 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 20 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3,000.00 · Expires 2028-10-29 | Direct | 25 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 25 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2031-03-18 | Direct | 293,479 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 293,479 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2031-11-04 | Direct | 42,059 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 42,059 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.91 · Expires 2033-02-17 | Direct | 106,762 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 106,762 F2: The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2034-02-13 | Direct | 394,737 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 394,737 F3: The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2035-02-14 | Direct | 768,979 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 768,979 F4: The option vests and becomes exercisable to the extent of 384,490 shares on February 14, 2025 and 384,489 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is currently exercisable.
F2: The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
F3: The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.
F4: The option vests and becomes exercisable to the extent of 384,490 shares on February 14, 2025 and 384,489 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 60,000 | Not disclosed Strike: $3.73 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 27 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2026-06-10 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F9 · derivative.exercise_date: The option is exercisable to the extent of 20,000 shares on each of June 10, 2017, June 10, 2018 and June 10, 2019. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 25,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 26 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2025-09-04 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F8 · derivative.exercise_date: The option is exercisable to the extent of 8,334 shares on September 4, 2016 and 8,333 shares on each of September 4, 2017 and September 4, 2018. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 25,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 25 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-09-04 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F8 · derivative.exercise_date: The option is exercisable to the extent of 8,334 shares on September 4, 2016 and 8,333 shares on each of September 4, 2017 and September 4, 2018. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 37,500 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 24 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2024-10-23 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F7 · derivative.exercise_date: The option is exercisable to the extent of 12,500 shares on each of October 23, 2015, October 23, 2016 and October 23, 2017. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 37,500 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 23 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2024-10-23 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F7 · derivative.exercise_date: The option is exercisable to the extent of 12,500 shares on each of October 23, 2015, October 23, 2016 and October 23, 2017. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 2,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 22 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2022-05-02 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 2,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 21 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2022-05-02 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 2,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 20 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2024-03-11 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 2,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 19 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2024-03-11 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 12,500 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 18 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2024-02-18 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F6 · derivative.exercise_date: The option is exercisable to the extent of 4,167 shares on each of February 18, 2014 and February 18, 2015, and 4,166 shares on February 18, 2016. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 12,500 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 17 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2024-02-18 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F6 · derivative.exercise_date: The option is exercisable to the extent of 4,167 shares on each of February 18, 2014 and February 18, 2015, and 4,166 shares on February 18, 2016. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 5,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 16 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2023-10-04 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5 · derivative.exercise_date: The option is exercisable to the extent of 2,500 shares on each of October 4, 2013 and October 4, 2014. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 5,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 15 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2023-10-04 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5 · derivative.exercise_date: The option is exercisable to the extent of 2,500 shares on each of October 4, 2013 and October 4, 2014. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 4,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 14 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2022-12-07 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 2,000 shares on each of December 7, 2012 and December 7, 2013. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 4,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 13 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2022-12-07 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 2,000 shares on each of December 7, 2012 and December 7, 2013. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 5,500 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 12 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2022-05-02 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3 · derivative.exercise_date: The option is exercisable to the extent of 500 shares on each of May 3, 2013, May 3, 2014 and May 3, 2015, became exercisable to the extent of 1,000 shares based on the satisfaction of certain conditions and is exercisable to the extent of 3,000 shares subject to the satisfaction of certain conditions. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 5,500 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 11 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,500 shares Expires 2022-05-02 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3 · derivative.exercise_date: The option is exercisable to the extent of 500 shares on each of May 3, 2013, May 3, 2014 and May 3, 2015, became exercisable to the extent of 1,000 shares based on the satisfaction of certain conditions and is exercisable to the extent of 3,000 shares subject to the satisfaction of certain conditions. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 2,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 10 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2022-02-09 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 1,000 shares on each of February 10, 2012 and February 10, 2013. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 2,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 9 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2022-02-09 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 1,000 shares on each of February 10, 2012 and February 10, 2013. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 1,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 8 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2021-11-15 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 1,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 7 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2021-11-15 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 150 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 6 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150 Underlying: Common Stock · 150 shares Expires 2021-06-23 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 150 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 5 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150 shares Expires 2021-06-23 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 4,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 4 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2021-04-04 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option is exercisable to the extent of 2,000 shares on each of April 5, 2011 and April 5, 2012. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 4,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 3 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2021-04-04 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option is exercisable to the extent of 2,000 shares on each of April 5, 2011 and April 5, 2012. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 20:01 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001567619-18-004860 · doc1.xml · derivative · entry 17 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-10-29 F11 · derivative.exercise_date: The option is exercisable to the extent of 33,334 shares on October 29, 2019, and 33,333 shares on each of October 29, 2020 and October 29, 2021. Read SEC document |
| July 12, 2017 Filed Jul 14, 2017 16:05 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 80,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001140361-17-027866 · doc1.xml · derivative · entry 16 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2027-07-12 F10 · derivative.exercise_date: The option is exercisable to the extent of 26,667 shares on each of July 12, 2018 and July 12, 2019, and 26,666 shares on July 12, 2020. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 25,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 24 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2025-09-04 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F8 · derivative.exercise_date: The option is exercisable to the extent of 8,334 shares on September 4, 2016 and 8,333 shares on each of September 4, 2017 and September 4, 2018. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 25,000 | Not disclosed Strike: $7.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 23 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-09-04 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F8 · derivative.exercise_date: The option is exercisable to the extent of 8,334 shares on September 4, 2016 and 8,333 shares on each of September 4, 2017 and September 4, 2018. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 37,500 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 22 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2024-10-23 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F7 · derivative.exercise_date: The option is exercisable to the extent of 12,500 shares on each of October 23, 2015, October 23, 2016 and October 23, 2017. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 37,500 | Not disclosed Strike: $6.60 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 21 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2024-10-23 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F7 · derivative.exercise_date: The option is exercisable to the extent of 12,500 shares on each of October 23, 2015, October 23, 2016 and October 23, 2017. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 2,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 20 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2022-05-02 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 2,000 | Not disclosed Strike: $28.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 19 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2022-05-02 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 2,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 18 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2024-03-11 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 2,000 | Not disclosed Strike: $10.60 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 17 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2024-03-11 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 12,500 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 16 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2024-02-18 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F6 · derivative.exercise_date: The option is exercisable to the extent of 4,167 shares on each of February 18, 2014 and February 18, 2015, and 4,166 shares on February 18, 2016. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 12,500 | Not disclosed Strike: $13.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 15 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2024-02-18 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F6 · derivative.exercise_date: The option is exercisable to the extent of 4,167 shares on each of February 18, 2014 and February 18, 2015, and 4,166 shares on February 18, 2016. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 5,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 14 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2023-10-04 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5 · derivative.exercise_date: The option is exercisable to the extent of 2,500 shares on each of October 4, 2013 and October 4, 2014. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 5,000 | Not disclosed Strike: $12.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 13 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2023-10-04 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5 · derivative.exercise_date: The option is exercisable to the extent of 2,500 shares on each of October 4, 2013 and October 4, 2014. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 4,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 12 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2022-12-07 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 2,000 shares on each of December 7, 2012 and December 7, 2013. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 4,000 | Not disclosed Strike: $30.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 11 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2022-12-07 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 2,000 shares on each of December 7, 2012 and December 7, 2013. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 5,500 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 10 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2022-05-02 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3 · derivative.exercise_date: The option is exercisable to the extent of 500 shares on each of May 3, 2013, May 3, 2014 and May 3, 2015, became exercisable to the extent of 1,000 shares based on the satisfaction of certain conditions and is exercisable to the extent of 3,000 shares subject to the satisfaction of certain conditions. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 5,500 | Not disclosed Strike: $28.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 9 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,500 shares Expires 2022-05-02 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3 · derivative.exercise_date: The option is exercisable to the extent of 500 shares on each of May 3, 2013, May 3, 2014 and May 3, 2015, became exercisable to the extent of 1,000 shares based on the satisfaction of certain conditions and is exercisable to the extent of 3,000 shares subject to the satisfaction of certain conditions. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 2,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 8 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2022-02-09 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 1,000 shares on each of February 10, 2012 and February 10, 2013. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 2,000 | Not disclosed Strike: $21.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 7 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2022-02-09 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 1,000 shares on each of February 10, 2012 and February 10, 2013. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 1,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 6 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2021-11-15 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 1,000 | Not disclosed Strike: $20.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 5 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2021-11-15 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 150 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 4 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150 Underlying: Common Stock · 150 shares Expires 2021-06-23 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 150 | Not disclosed Strike: $25.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 3 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150 shares Expires 2021-06-23 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 4,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 2 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2021-04-04 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option is exercisable to the extent of 2,000 shares on each of April 5, 2011 and April 5, 2012. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.